DexCom shares saw modest gains during the regular session, bolstered by positive market sentiment following the October 2 release of a company report highlighting significant growth opportunities for continuous glucose monitoring in Type 2 diabetes care. The report identified that 58% of Type 2 patients on GLP-1 medications represent a substantial expansion opportunity, which helped drive investor interest alongside news of Bright Rock Capital Management LLC acquiring 36,000 shares during the third quarter. The stock is facing mild pressure in after-hours trading, potentially reflecting a cooling off after the recent news-driven momentum and general movement within the medical device sector, where peers like Insulet and Abbott also saw gains during the regular session.